T-LGL leukemia in the presence of an NK-cell proliferation has been reported before, but the clonal nature of the NK-cell population could not be established. 8 The here presented case represents the first description of the coexistence of T-LGL and chronic NK-LGL populations with 'clonal' immunophenotype, which was confirmed by molecular studies. Remarkably, two different clonal chromosomal aberrations were present in the T-LGL and NK-LGL proliferations. Furthermore, this case illustrates the relatively indolent clinical course of T-LGL and chronic NK-LGL leukemia and confirms that genetic instability in LGL leukemias is less common and more subtle than in other mature T-/NK-cell malignancies.
Certain subtypes of childhood acute leukaemia are characterized by specific chromosomal translocations. Interestingly, some of these translocations have been shown to arise in utero as illustrated by their presence in neonatal blood spots from children, who later developed leukaemia.
1,2 Accordingly, information on risk factors for the prenatal emergence of such translocations, most likely representing an initial step in leukaemia development, are important to the understanding of childhood leukaemias.
Fusion gene transcripts resulting from chromosomal translocations can be detected and quantified by quantitative realtime polymerase chain reaction (qRT-PCR) using generic assays. Applied on cord blood samples, this technology may be relevant in the effort to characterize the epidemiology of pre-leukaemia, that is the prevalence and risk factors for pre-leukaemic cell clones in healthy neonates. 3 However, as RNA is very unstable, the sampling process in itself may result in RNA degradation and thus potentially false-negative results. This problem may be particularly pertinent to large-scale studies in which the time frame from sample collection to RNA processing extends beyond a few hours. Moreover, whereas the stability of house keeping and fusion gene transcripts has been assessed in peripheral blood and bone marrow, such information is not available for cord blood (CB) samples. 4, 5 In this study, we evaluated the significance of the time interval between acquisition of a CB sample and its processing, variable temperature during storing and the impact of RNA extraction protocols in degraded samples. The time-dependent degradation of RNAs in RNA unstabilized CB samples was evaluated by amplification of control genes and by mimicking a pre-leukaemic TEL-AML1-positive clone. Furthermore, we evaluated the use of a single-step method for purification of poly(A) þ RNA from cell lysate using paramagnetic oligo(dT) microbeads in comparison to total RNA in a TaqMan-based qRT-PCR set-up. 6 CB samples were collected into ethylenediaminetetraacetic acid Vacutainer tubes from 20 healthy newborns at the Clinic of Obstetrics, Copenhagen University Hospital, Denmark. In the first-sample set-up, the CB samples were divided into five identical tubes (1 ml whole CB per tube). The first tube was processed within an hour from sample collection (day 0), whereas the other four tubes were processed 24 (day 1), 48 (day 2), 72 (day 3) and 96 h (day 4) after sample collection. The time-dependent degradation rate was evaluated by amplification of Abelson (ABL) and Glucuronidase (GUS) control genes using poly(A) þ -extracted RNA. Furthermore, the time-dependent degradation of poly(A) þ -extracted RNA was compared with parallel extracted total RNA, by the use of two different sets of PCR primers and TaqMan probes for the ABL control gene located in the 5 0 -(cap) and 3 0 -end (poly(A) tail) of the transcript, respectively. In the second set-up, one tube from five representative samples was stored at 41C for 24 h before processing in order to evaluate the temperature-dependent degradation rate, measured by amplification of the ABL gene. In order to mimick a TEL-AML1-positive clone at cell levels of 10 À3 and 10
À4
, mononucleated cells from bone marrow samples obtained at diagnosis from two children with t(12;21)-positive acute lymphoblastic leukaemia (ALL) were diluted in t(12;21)-negative peripheral blood obtained from the same child in remission after completion of the chemotherapy. The study was approved by the Danish Data Protection Agency (2003-41-2726 ) and the Scientific Ethics Committee for the Copenhagen and Frederiksberg Municipalities (01-052/03). All parents gave informed consent.
The CB samples were density separated using Lymphoprep (Axis-Shield, Oslo, Norway) and RNA was extracted from the isolated mononuclear cells (MNCs). Poly(A) þ RNA was isolated using the GenoPrep Direct messenger RNA (mRNA) Kit (GenoVision, Oslo, Norway) following the manufacturer's protocol. Fifty microlitre beads isolate poly(A) þ RNA from up to 2 Â 10 6 cells with a binding capacity of 550 pmol polyadenylated RNAs in a semi-automated procedure on a KingFisher mL platform (Thermo Labsystems, Helsinki, Finland). The KingFisher platform enables RNA isolation of up to 15 samples simultaneously in 20 min suitable for large-scale RT-PCR studies. Total RNA was extracted using the RiboPure-Blood Kit (Ambion, Cambridgeshire, UK) following the manufacturer's protocol, except for the optional DNase I digestion step. The concentration of the extracted RNA was measured using the Agilent Bioanalyzer 2100 (Agilent, Waldbronn, Germany) as described in the total RNA Nano assay and mRNA Nano assay, respectively. In case of total RNA concentrations of less than 100 ng/ml, the concentration was increased by evaporation. The median RNA integrity number (RIN value) was 9.4 and 9.2 in total RNA processed at day 0 and 1, respectively indicating intact RNA. However, the median RIN values decreased with increasing time interval from sampling to processing to values of 7.3 (day 2), 6.5 (day 3) and 5.6 in samples processed on day 4, indicating partially degraded RNA.
For reverse transcription, 12 ml of poly(A) þ RNA out of a 50 ml preparation or 1 mg of total RNA was added to a 20 ml reaction using 1 Â PCR buffer, 5 mM MgCl 2 , 1 mM of each dNTP, 25 mM random hexamers, 1 U RNase Inhibitor and 2.5 U MuLV Reverse Transcriptase (Applied Biosystems, Foster City, CA, USA). The synthesis programme was 421C for 30 min, followed by 991C for 5 min. RT-PCR was performed using an ABI7700 platform (Applied Biosystems, Foster City, USA). The sequences of primers and probes for the TEL-AML1 fusion gene and the 5 0 -ABL transcript (exon 1a þ 2) are described elsewhere. 7 The sequences of 3 0 ABL primers and probe (exon 10 þ 11) are available on request from the corresponding author. For PCR, 5 ml of cDNA were amplified in 30 ml reactions (equivalent of 250 ng total RNA) using 15 ml mastermix (Applied Biosystems, Foster City, USA), 300 nM of each primer and 200 nM probe. The PCR programme was 501C for 2 min and 951C for 10 min followed by 50 cycles of two-step PCR, 951C for 15 s and 601C for 1 min. The qRT-PCR result for each RNA preparation was determined as the mean of three parallel PCR experiments and expressed as cycle threshold (C t ) values. The baseline cycle range was set to 3-15 and a threshold value of 0.05. Cycle threshold values from amplification of the house keeping genes for each of the RNA protocols were compared using Wilcoxonsigned rank test for paired data (SPSS 13.0 software, Chicago, IL, USA).
In degraded samples, the mRNA is likely to be fragmentated and targets in the 5 0 -end of the transcripts lost. In addition, deadenylation initiates mRNA decay. 8 This should theoretically have a more profound influence on poly(A) þ -extracted RNA, as partially degraded transcripts would less likely to be caught by the magnetic beads. We evaluated the integrity of both poly(A) þ and total RNA over time by calculating a DC t (Ct exon11 ÀC t exon1 ) value from amplification of two different positions in the ABL transcript. Here, we observed a reduced integrity of the 3 0 -poly(A) tail in both poly(A) þ and total RNA in all samples processed after 24 h, measured by an increase of the mean DC t þ RNA and B2.5 for total RNA were observed (Mann-Whitney U-test, P ¼ 0.001 and 0.003, respectively). A significant difference between the two methods was observed in samples processed after 48 and 72 h (Wilcoxon, P ¼ 0.03 and 0.02, respectively).
Letters to the Editor values of B2.0 for poly(A)
þ RNA and B2.5 for total RNA (Figure 1 ). Although these findings indicate a slightly significant advantage of using polyadenylated RNA rather than total RNA in degraded samples, the difference is so moderate that either method can be recommended until the issue has been further explored.
In samples processed 48 h or later from collection, we observed a significant and progressive increase in median C t values of both control genes (Figure 2a) . Compared with day 1 tube stored at room temperature, an increase of one C t was observed in tubes stored at 41C for 24 h (P ¼ 0.03). Both results indicate that these transcripts are rapidly degraded in CB ex vivo and CB samples should preferably be processed on the day of sampling and if stored, then preferably at room temperature, similar to recommendations for peripheral blood and bone marrow samples. 5 The RT-PCR results from the diluted TEL-AML1-positive cells were similar to those obtained for the ABL and GUS control genes in the first set-up. Thus, the C t values were increased in parallel (TEL-AML1 vs ABL; R 2 ¼ 0.8 for both dilutions) and the mean C t values for the two TEL-AML1-positive 10 À3 and 10 À4 dilutions were increased from 32.5 and 34.4 on day 0 to 34.5 (10 À3 ) and 40.5 (10 À4 ) on days 4 and 3, respectively. However, the leukaemic cells were isolated from diagnostic bone marrow samples and may thus neither reflect the stability nor level of TEL-AML1 transcripts in a pre-leukaemic clone.
The expression of the control genes in the poly(A) þ RT-PCR was higher when compared with the total RNA RT-PCR (Figure 2b) . By increasing the amount of total RNA from 1 to 3 mg in the cDNA synthesis (250 and 750 ng RNA/cDNA, respectively), the detection of the ABL gene was increased B2.5-fold in analyses of 3 mg total RNA corresponding with a three-fold increase in template (data not shown). The majority of total RNA is ribosomal RNA with mRNA making up only 1-5% of total RNA. Our data may simply reflect a lower concentration of transcripts in 1 mg of total RNA compared with 12 ml of poly(A) þ RNA. However, the RNA yield from MNC isolated by Lymphoprep is low owing to the selective exclusion of irrelevant cells, which may limit the possibility for adding more than 1 mg RNA per 20 ml reaction volume. 4 RNA stabilization agents, such as the PAXgene bedside system, may prevent the RNA decay. The PAXgene procedure extracts RNA from all cell types, including reticulocytes, which contain high amounts of irrelevant globin transcripts. 4 As CB contain a high number of nucleated red blood cells, the applicability of the system may be questionable and accordingly, we did not test the system.
In conclusion, CB samples should preferably be processed on the day of sampling, as processing later than 24 h after sample collection leads to a decrease in RT-PCR sensitivity especially for samples stored at 41C. Not taking these precautions into account may lead to false-negative results in samples with preleukaemic clones at cell levels of 10 À4 or lower. No major differences in poly(A) þ and total RNA extraction methods were observed in degraded samples, although the data indicate an advantage of the poly(A) þ protocol. The median C t value was increased in the total RNA RT-PCR assay compared with the poly(A) þ RT-PCR assay (Pp0.005 from 0 to 72 h); however, the difference was not significant after 96 h (P ¼ 0.09).
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by periods of relapse and remission of neurological symptoms and progression of disability over time. Although the etiology of MS is unknown, most researchers consider it to be an immune-mediated disease. Mitoxantrone, a DNA topoisomerase II inhibitor used in cancer therapy, was the first immunosuppressant agent to receive approval from the USA Food and Drug Administration and the European Union for treatment of worsening relapsing/remitting, secondary progressive and progressive-relapsing MS.
Therapy-related acute myeloid leukemia (t-AML) may occur in two forms: the first is preceded by a longer lasting myelodysplastic phase, it is associated with alkylating substances and or ionizing radiation and is related to unbalanced chromosomal abnormalities, including deletions of chromosome 5 or 7. The second form is characterized by a short latency, acute onset and cytogenetic changes similar to de novo leukemias (e.g., translocations involving 11q23 or 8;21 or 15;17) and is associated with the use of DNA topoisomerase II inhibitors (such as epipodophyllotoxins, anthracyclines, carboplatin and mitoxantrone). 1 Over the last few years, several reports have indicated that the incidence of t-AML in the population of MS patients treated with mitoxantrone is higher than the risk of de novo AML in the general population. The occurrence of acute promyelocytic leukemia (APL) in MS patients treated with mitoxantrone has been well documented (Table 1) . [2] [3] [4] [5] [6] We report two new cases of APL in MS patients following treatment with mitoxantrone.
The first patient, a 21-year-old woman with MS since 1999, started to suffer from progressive-relapsing disease in February 2001 and was treated with beta-interferon followed by 10 courses of mitoxantrone (12 mg/m 2 ; total dose 170 mg) from August 2002 to December 2003. A second course of betainterferon was started in March 2005 but had to be interrupted 3 months later for severe fatigue, profuse sweating, gum bleeding and general status worsening. Blood tests showed leukocytopenia (white blood cell (WBC) 1.19 Â 10 9 /l), anemia (hemoglobin 7.9 mg/dl) and thrombocytopenia (platelets 30 Â 10 9 /l). Physical examination revealed pallor, mild hepatosplenomegaly and petechiae. Bone marrow aspirate demonstrated a markedly hypercellular marrow with 80% blast cells containing Auer rods. Coagulation parameters were consistent with consumption coagulopathy.
Immunophenotyping identified the blast cells CD45 þ , CD13 þ , CD33 þ , CD34À and HLA-DRÀ. Cytogenetic evaluation showed 46XX,t(15;17)(q22;q12). PML/RAR-alpha fusion gene rearrangement was confirmed by fluorescence in situ hybridization and molecular analysis. A diagnosis of APL (FAB M3) was formulated. The patient was treated with all-trans retinoic acid (ATRA) 45 mg/m 2 for 30 days and intravenous 
